Chinese biotech firm Brii jumps on China Resources partnership

China Resources Pharmaceutical

19/07/2022 07:37

** Shares of infectious disease therapies developer Brii
Biosciences Ltd  2137.HK  jump as much as 8.1% to HK$10.70
    ** Stock to mark its biggest daily pct rise since July 11,
if gains hold; up after three consecutive sessions of losses
    ** Beijing-based co says majority-owned TSB Therapeutics
(Beijing) is partnering with China Resources Pharmaceutical
Commercial Group to advance stockpiling and channel
distribution, among others  urn:newsml:reuters.com:*:nFWN2YZ21V
    ** Says two parties are working together to ensure timely
drug supply that supports COVID-19 prevention and control
efforts in China
    ** The Hang Seng Commerce & Industry Index  .HSNC  falls
1.1%, the healthcare index  .HSCIH  eases 1%, and the benchmark
Hang Seng Index  .HSI  slips 0.9%
    ** As of last close, the stock had fallen 69.9% this year

 (Reporting by Donny Kwok)
 ((donny.kwok@thomsonreuters.com))